SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics board approves financial results

16 Aug 2021 Evaluate
Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 Lasa Supergenerics has informed that the Board of Directors in their meeting held on August 14, 2021 which was commenced at 12:00 Noon and concluded at 03: 30 pm has considered and approved the statement of un-audited financials result along with Limited Review Report for the quarter ended June 30, 2021.

The above information is a part of company’s filings submitted to BSE.

Lasa Supergenerics Share Price

8.46 -0.01 (-0.12%)
20-Apr-2026 14:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.75
Dr. Reddys Lab 1233.95
Cipla 1231.60
Zydus Lifesciences 938.70
Lupin 2328.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×